Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Find more results for ANAC
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 13.19 - 68.90
Open     -
Vol / Avg. 0.00/677,696.00
Mkt cap 2.86B
P/E     -
Div/yield     -
EPS -1.86
Shares 43.75M
Beta 1.38
Inst. own 96%
Aug 5, 2015
Q2 2015 Anacor Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 9, 2015
Anacor Pharmaceuticals Inc Annual Shareholders Meeting - 2:30PM EDT - Add to calendar
May 13, 2015
Anacor Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Anacor Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 6, 2015
Q1 2015 Anacor Pharmaceuticals Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 Anacor Pharmaceuticals Inc Earnings Release
Mar 12, 2015
Q4 2014 Anacor Pharmaceuticals Inc Earnings Call - Webcast
Mar 12, 2015
Q4 2014 Anacor Pharmaceuticals Inc Earnings Release
Mar 3, 2015
Anacor Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -84.91% -421.28%
Operating margin -77.28% -449.66%
EBITD margin - -436.51%
Return on average assets -24.53% -45.72%
Return on average equity -68.66% -87.03%
Employees 100 -
CDP Score - -


1020 East Meadow Circle
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company has discovered, synthesized and developed eight molecules that are in development. Its lead product candidates include two topically administered dermatologic compounds tavaborol and AN2728. The Company has discovered three investigational compounds that it has out-licensed for further development. The compound is licensed to Eli Lilly and Company (Lilly) for the treatment of an animal health indication. The second compound, AN5568 is indicated for the potential treatment of human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline LLC (GSK) for development in tuberculosis (TB).It also has a pipeline of other topical and systemic boron-based compounds which include, AN2718, AN2898 and AN3365.

Officers and directors

Paul L. Berns Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Geoffrey M. Parker Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Vincent P. Ippolito Executive Vice President, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Ryan T. Sullivan Senior Vice President, General Counsel, Secretary
Age: 39
Bio & Compensation  - Reuters
Sanjay Chanda Ph.D. Senior Vice President - Drug Development
Age: 50
Bio & Compensation  - Reuters
Kirk R. Maples Ph.D. Senior Vice President - Program Management
Age: 56
Bio & Compensation  - Reuters
Jacob J. Plattner Ph.D. Senior Vice President - Research
Age: 68
Bio & Compensation  - Reuters
Carmen R. Rodriguez Ph.D. Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 66
Bio & Compensation  - Reuters
Lee T. Zane M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
William J. Rieflin Lead Independent Director
Age: 55
Bio & Compensation  - Reuters